source
- Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdownAmgen has shared more data from a phase 3 Sjögren’s disease trial that dazzled analysts, digging into the details that could shape its showdown with Novartis.
- FDA releases draft guidance for early-phase first-in-human studies of solid-tumor therapiesThe U.S. Food and Drug Administration has issued draft guidance to help sponsors design early-phase first-in-human IND studies for investigational drugs and biologics targeting solid tumors. The g…